Paul A. Mahon - 15 Mar 2023 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: EVP & GENERAL COUNSEL
Issuer ticker: UTHR
Reported as of: 15 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2026, 16:31:44 UTC
Prior SEC filing: 02 Mar 2023
Next SEC filing: 17 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

Paul A. Mahon filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 26 Feb 2026.

Key facts

This page summarizes Paul A. Mahon's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 26 Feb 2026, 16:31.

Change

Previous filing in this sequence was filed on 02 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001231589 Primary reporting owner

MAHON PAUL A

Relationship: EVP & GENERAL COUNSEL
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 26 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +49,860
Change %
Price: $0.000000
Shares after: 49,860
Date: 15 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,860
Exercise price: $217.50
Footnotes: F1

UTHR transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +7,796
Change %
Price: $0.000000
Shares after: 7,796
Date: 15 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,796
Exercise price: $0.000000
Footnotes: F2, F3, F4

UTHR transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +8,895
Change %
Price: $0.000000
Shares after: 8,895
Date: 15 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,895
Exercise price: $0.000000
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

Footnote F2

These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.

Footnote F3

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F4

Not applicable as restricted stock units do not have an expiration date.

Footnote F5

These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.